

# MDT assessment and referral for PEG tube in patients with MND

	Patient	Name		Date of	DOB.	Contact	Contact number		
details	name			birth		number			
leta	NHS number	NHS no.		Consultant	Consultant	Current	Inpatient ward no.: Location		
						location	Outpatient location:		
ient							Location		
Pati									
1: P	Clinical	Diagnosis	Past me	dical & surgic	al history:	PMH/PSH			
	diagnosis								
Step	Current	Medication	Is the pa	atient on anti	coagulant	No 🗆			
U,	medication:		c	or antiplatelet	t therapy?	Yes 🗆 (please	e list): List therapy		

2: Referral Criteria	Does the patient have any of the following Indicators? • 5 %weight loss from diagnosis • Respiratory impairment • Recurrent chest infections • Physical feeding difficulties or prolonged meal times • Cognitive changes • BMI <20 • Reduced oral intake • Bulbar symptoms	Does the patient have assumed mental capacity to make the decision to be referred for gastrostomy insertion?	Have the patient, family and carer been involved in a discussion and given relevant supporting information in a format that is appropriate to them in order to make an informed decision?		Has the patient given informed consent to be referred for consideration of gastrostomy insertion?	Is the patient under the care of the regional specialist respiratory service and had a baseline respiratory assessment or had a respiratory assessment within the last 3 months
STEP	YES □ NO □Continue to monitor & reassess if any changes	YES  VO NO Complete Mental Capacity Assessment	YES  VES  VO VEnsure discussion & information provided		YES NO  Reassess if patient decision changes in future	YES  VES  Solution YES  Solution Soluti
If 'yes' to all of the above Continue to step 3 and assess patient's level of risk				If 'no' to any of the above Do not refer to PEG MDT until all criteria met or discussion with MND MDT has taken place		

1. Identify patient's level of risk. Start by assessing the patient against the 'Red' criteria. If any indicators are ticked, this is the risk category for this patient.

2. If no indicators are selected from the 'Red' criteria, assess the patient against the 'Amber' criteria. If any indicators are ticked, this is the risk category for this patient.

3. If they do not meet the 'Red' or 'Amber' criteria, the patients risk category is 'Green'.

		Red (High risk)	Amber (moderate risk)	Green (low risk)
-	Respiratory	□ Recurrent chest infections	☐ Morning headache or orthopnoea	□No
eve		Abdominal paradox	□Breathlessness or increased respiratory rate	respiratory
Risk identification level		Reduced chest expansion	□Non-refreshing sleep or daytime sleepiness	symptoms or
tio		□SNIP <40cmH20 or has a poor sniff	□Shallow breathing	fatigue
ica		□ FVC <50% of predicted or has a	□Use of accessory muscles of respiration	□Poor speech
ltif		poor, ineffective cough	$\Box$ SNIP >40cmH20 or has an adequate sniff	volume
qei		□ FVC fall > 15% on lying flat	□FVC >50% of predicted or has effective cough	□Poor appetite
ik i		□Sp02 < 94% without known lung	□FVC fall <15% on lying flat	
Ris		disease or <92% with known lung	□Sp02 ≥ 94% without known lung disease	
ä		disease	or <u>&gt;</u> 92% with known lung disease	
STEP	Ventilation	□Unable to tolerate or has new non-	$\Box$ Established on non-invasive ventilation (NIV)	□Not on
S		invasive ventilation or tracheostomy	without issue	ventilation
	Weight	$\Box$ >10% weight loss with associated	$\Box$ >5% weight loss with no associated	□<5% weight
		respiratory symptoms	respiratory symptoms	loss
	Positioning	$\Box$ Unable to lay flat for <u>&gt;</u> 20 minutes	□Can lay flat for <u>&gt;</u> 20 minutes or more	□Can lay flat
				for <u>&gt;</u> 20
	Mental	□Poor concentration/memory	□Disturbed sleep	□No concerns
	state	□ Has confusion or hallucinations		

	Confirm	risk category:	Red 🗆 Amber 🗆	Green 🗌						
	Does the pa	tient have any	No contraindications 🗆 🛛 Active gastric ulceration/malignancy 🗆							
	of	f the following		EOL/limited life expectancy  Gastric outlet obstruction						
	cont	traindications:	Advance decision against gastrostomy  Large hiatus hernia					iernia 🗆		
			End stage dementia 🗆 Crohns disease							
			Current chest infection/pneumonia  Disseminated metastatic disease							
			Oesophageal constriction or obstruction   Liver disease							
			Morbid	obesity or thic	ck abdominal wall $\Box$	And	orexia ne	rvosa 🗆		
tio				Coagulati	on abnormalities 🗌		Pregr	nancy 🗆		
ma					cardial infarction $\Box$			onitis 🗆		
for				•	y/gastric surgery 🗆	Peri	toneal di	alysis 🗆		
4: PEG MDT further information			Gastro-oes	Gastro-oesophageal reflux with aspiration 🗆						
hei		e patient been	Yes $\Box$ date: Date No $\Box$ - All patients to be seen by dietitian prior to PEG.							
r,		by a dietitian?	Refer to local dietitian dept. for assessment.							
Т,		e patient been	Yes $\Box$ date: Date. No $\Box$ - All patients to be seen by SLT prior to PEG.							
Σ		by a Speech &	Refer to local SLT dept. for assessment							
ı ت	language therapist (SLT)?		Detectory Date							
Ē	What is the patients		Date taken: Date Weight (kg): Weight, Height (m): Height BMI:BMI							
P 4	Maisht hist	current:	Weight (kg): Weight. Height (m): Height BMI:BMI Weight history							
STEP ,	-	ory (E.G. usual	weight history							
•	weight, weight loss Blood results		HB: result PLT: result PT: result							
	Re	elevant further	Further comments or information							
	-	or information								
	Referrer details (complete in block capitals)									
	Name:	Name			Designation:	Designation				
	Signature:	Signature	Signature			Registration number	Date:	Date		

 If this patient meets the above criteria send this completed document to the PEG MDT and MND MDT:

 Email:
 stees.pegreferrals@nhs.net
 and stees.mnd@nhs.net

 Phone:
 07741616365 or ext 53574

 All patients will be discussed in the weekly PEG MDT, held each Friday morning. Referral needs to be sent to the PEG MDT by Thursday at 12 noon to be discussed at the PEG MDT that week.

MDT	Is this patient deemed appropriate to proce Yes  No If no please specify reason: Reason	eed with PEG?	<b>Confirm risk category based on all available information:</b> Red  Amber  Green					
PEG I	<b>Step 6:</b> PEG MDT to identify the route of PEG insertion appropriate for this patient							
by PI	Red (High risk) 🗆	Amber	moderate risk) 🗆	Green (Low risk) 🗆				
STEP 5: PEG MDT (for completion b	<ul> <li>Push gastrostomy to be inserted via trans-nasal endoscopy (TNE) in a seated position with no sedation, on a dedicated consultant list experienced in the care of patients with potential respiratory compromise.</li> <li>MND Specialist Nurse to be present during the procedure.</li> <li>If appropriate non-invasive ventilation must be available during &amp; post procedure.</li> <li>If there is a delay in procedure of more than 2-3 weeks, re-evaluate in MND MDT</li> </ul>	<ul> <li>dedicated co experienced with potentia compromise</li> <li>Pull PEG tech however con technique if contraindica</li> <li>If appropriat ventilation m &amp; post proce</li> <li>If there is a co</li> </ul>	in the care of patients al respiratory nnique to be used, usider TNE push PEG use of sedation is ted. e, non-invasive nust be available during	<ul> <li>Gastrostomy may go ahead on a routine list using a pull PEG technique.</li> <li>Continue to monitor and if there is a delay of more than 6 weeks, re-evaluate in MND MDT</li> </ul>				

## All high and moderate risk patients:

- To have a guaranteed bed prior to procedure going ahead on ward areas trained in the use of NIV, PEGs and caring for those with a diagnosis of MND. This would usually be neurosciences, gastroenterology or respiratory services
- Any patient who has had a change in respiratory function or is at risk of refeeding syndrome is to be admitted the night before the procedure.

## Low risk patients:

• To have a guaranteed bed prior to procedure going ahead on ward areas trained in the use of PEG and caring for those with a diagnosis of MND. This would usually be neurosciences, gastroenterology or respiratory services

## All patients:

- To be screened prior to admission following Trust infection prevention and control guidance.
- To remain an inpatient for at least 24 hours post procedure. This may be longer if the patient is at risk of refeeding syndrome and/or social concerns.
- To have the appropriate gastrostomy care pathway followed.
- To be reviewed by dietitian prior to discharge. For SLT review if appropriate.
- To receive PEG nurse review/senior medical review within first 24 hours following procedure. Patient will not be discharged prior to this review.
- To receive PEG training via Nutricia Nurse prior to discharge and receive Nutricia nurse review within 1-2 weeks of discharge from hospital.

#### Follow up:

- If sutures are in-situ, an appointment will be made prior to discharge for removal of these 7 days post procedure.
- All patients to receive dietetic follow up via MND clinic, if able to attend or local dietetic service at home.
- All patients to receive a PEG review appointment in Endoscopy Department, if able to attend, within 3-6 months of discharge from hospital.

## Consider the following if sedating an individual with MND undergoing endoscopic pull gastrostomy:

- If established on NIV this should be available and ready to use whilst in endoscopy and a nasal mask is recommended. Oxygen should not be used as standard procedure, but should be available throughout.
- Throat spray should not be used as this can potentially increase the risk of aspiration and minimal sedation is normally required with midazolam. Fentanyl should not be required.
- Desaturation may occur in this patient group when lying flat, therefore a trial of lying flat unsedated for 5 minutes whilst monitoring using a saturation probe is recommended.
- If oxygen saturations fall then it may be necessary to sit the patient up slightly and repeat the above step. You may want to consider using patients own NIV if available.
- If saturations are stable you can proceed with sedation. A suggested dose of midazolam is 0.5 1mg initially and observing for a further 5 minutes.
- Midazolam's peak onset of action is at 3-6 minutes; therefore it is necessary to wait an appropriate time before assessing whether more is required.
- An acceptable oxygen saturation range for those with MND and known respiratory involvement (or those with NIV) is 88-92%. For those without known respiratory involvement an acceptable oxygen saturation range is 92-94%.
- Depending on level of sedation & O2 saturations you can either proceed with procedure or give further sedation. It is suggested that no more than 0.5mg increments of midazolam is given at a time.
- If a minimally sedated patient is not tolerant of intubation you can try rotating them onto their side for intubation then rotating back onto their back for the gastrostomy insertion.

#### Consider the following in an individual with MND undergoing trans-nasal endoscopic push gastrostomy:

- If established on NIV this should be available and ready to use whilst in endoscopy and a full face mask is recommended. Oxygen should not be used as standard procedure, but should be available throughout.
- Sedation should not be required as this can cause further respiratory compromise.
- Nasal spray should be used to numb the nasopharyngeal tract only.
- The patient should remain upright throughout the procedure and only reclined if tolerable and no desaturation noted.
- If oxygen saturations fall, sit the patient upright and ensure O2 saturations are within range prior to recommencing procedure. You may want to consider using patients own NIV if available.
- An acceptable oxygen saturation range for those with MND and known respiratory involvement (or those with NIV) is 88-92%. For those without known respiratory involvement an acceptable oxygen saturation range is 92-94%.

References

- 1. National Institute for Health and Care Excellence. (2016). Motor Neurone Disease: assessment and management. (NICE Guideline No. 143). https://www.nice.org.uk/guidance/ng42
- 2. British Thoracic Society, (2017). BTS guideline for oxygen use in adults in healthcare and emergency settings. <u>https://www.brit-thoracic.org.uk/quality-improvement/guidelines/emergency-oxygen/</u>
- 3. ProGas Study G (2015) Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. Lancet Neurol. 14: 702-709.
- 4. McCulloch A et al. Nasal unsedated seated percutaneous endoscopic gastrostomy (nuPEG): a safe and effective technique for percutaneous endoscopic gastrostomy placement in high- risk candidates. Frontline Gastroenterology 2017; (0)1-5